| Specific determination and identification of cross-linked fibrin degradation products in patients under thrombolytic therapy for myocardial infarction. | |
| | |
MedLine Citation:
|
PMID: 3114888 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We have demonstrated that the specific determination and identification of plasma FbDP alone is not sufficient to follow the effectiveness of thrombolytic therapy. Some patients who received an intravenous infusion of rt-PA for myocardial infarction had very high plasma FbDP levels, although no recanalization was observed angiographically. Since in many cases the FbDP levels increased after recanalization, it is assumed that rethrombosis may occur during and after t-PA treatment. |
| | |
Authors:
|
J Soria; C Soria; M Mirshahi; M Xi; M Mirshahi; M M Samama; J P Caen |
Related Documents
:
|
1909218 - Comparative effects of apsac and rt-pa on infarct size and left ventricular function in... 10603508 - Time as an adjunctive agent to thrombolytic therapy. 11213858 - A review of available fibrin-specific thrombolytic agents used in acute myocardial infa... 9290398 - Thrombolytic treatment for myocardial infarction: an examination of practice in 39 unit... 9502628 - Influence of collateral circulation on in-hospital death from anterior acute myocardial... 7626868 - Declining risk of reoperative valvular surgery. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Seminars in thrombosis and hemostasis Volume: 13 ISSN: 0094-6176 ISO Abbreviation: Semin. Thromb. Hemost. Publication Date: 1987 Apr |
Date Detail:
|
Created Date: 1987-10-07 Completed Date: 1987-10-07 Revised Date: 2006-03-07 |
Medline Journal Info:
|
Nlm Unique ID: 0431155 Medline TA: Semin Thromb Hemost Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 223-7 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
diagnostic use Antibody Specificity Collodion Electrophoresis, Polyacrylamide Gel Fibrin Fibrinogen Degradation Products / analysis* Fibrinolytic Agents / pharmacology, therapeutic use* Humans Infusions, Intravenous Methods Myocardial Infarction / blood, drug therapy* Protein Conformation Recombinant Proteins / administration & dosage, therapeutic use Sodium Dodecyl Sulfate Tissue Plasminogen Activator / administration & dosage, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Fibrin Fibrinogen Degradation Products; 0/Fibrinolytic Agents; 0/Recombinant Proteins; 151-21-3/Sodium Dodecyl Sulfate; 9004-70-0/Collodion; EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Optimal dosage regimens of tissue-type plasminogen activator.
Next Document: A critical re-examination of the economics of blindness prevention under the Onchocerciasis Control ...